Aromatase inhibitorFDA-approvedAdjuvant
Letrozole
How it works
Blocks the aromatase enzyme, reducing estrogen production and inhibiting cancer cell growth.
Cancer types
Breast Cancer— ER-positive
Prostate Cancer— All patients
Efficacy
In clinical trials, letrozole reduced the risk of breast cancer recurrence in ER-positive patients.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Aromatase Inhibitors Linked to Liver Damage in Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Comparing Injectable and Oral Letrozole for Breast Cancer Treatment | Breast Cancer | phase-1 | — | Source → |
| Evaluating Zanidatamab in Early Stage HER2+ Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing New Treatment for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Abemaciclib and Letrozole in Rare Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Study of Avutometinib, Defactinib, and Letrozole for Low-Grade Serous Ovarian Cancer | Ovarian Cancer | phase-2 | — | Source → |
| Evaluating Dalpiciclib with or without Entinostat and Letrozole in Early Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Researchers Explore New Treatment Approach for Endometrial Cancer | Ovarian Cancer | observational | — | Source → |
| Combination Therapy Shows Promise in Rare Male Breast Cancer | Breast Cancer | observational | — | Source → |
| New Delivery Method for Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Combining two treatments for hormone receptor positive breast cancer | Breast Cancer | phase-2 | The estimated median progression-free survival for the combination was 17.7 months versus 14.6 months for letrozole alone. | Source → |
| CDK4/6 Inhibitors and Endocrine Therapy for Metastatic Breast Cancer | Breast Cancer | phase-3 | Ribociclib combined with letrozole significantly improved PFS over letrozole alone. | Source → |
| Letrozole May Help Manage Rare Uterine Tumors | Lung Cancer | observational | — | Source → |
| Researchers Treat Breast Cancer with Letrozole and Abemaciclib | Breast Cancer | observational | — | Source → |
| Rare Cancer Responds to Combination Therapy | Ovarian Cancer | lab-study | — | Source → |
| Alpelisib and Letrozole May Help Some Breast Cancer Patients | Breast Cancer | phase-2 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.